Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4930893 | 0.82 | LMNA (0.46) | KCNH2ALDH1A1MAPTGPR119LMNA | |
| SCHEMBL13344755 | 0.79 | MAPT (0.46) | ALDH1A1MAPTGPR119LMNASMN1; SMN2 | |
| SCHEMBL4928045 | 0.79 | MEN1 (0.44) | KCNH2ALDH1A1MAPTGPR119LMNA | |
| SCHEMBL4930131 | 0.78 | RPS6KB1 (0.47) | ALDH1A1SMN1; SMN2MEN1KMT2ACYP2C19 | |
| SCHEMBL4923594 | 0.78 | KCNH2 (0.40) | KCNH2ALDH1A1MAPTGPR119LMNA | |
| SCHEMBL4929222 | 0.78 | LMNA (0.49) | KCNH2ALDH1A1MAPTGPR119LMNA | |
| SCHEMBL13344713 | 0.76 | L3MBTL1 (0.54) | ALDH1A1MAPTGPR119LMNASMN1; SMN2 | |
| SCHEMBL4930918 | 0.76 | LMNA (0.50) | KCNH2ALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL4930903 | 0.75 | KCNH2 (0.40) | KCNH2ALDH1A1MAPTGPR119LMNA | |
| SCHEMBL4930003 | 0.75 | GPR119 (0.45) | MAPTGPR119LMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| EP-1750727-A2 | KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005117909-A2 | KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | KCNH2 3918/4885ALDH1A1 4305/4885MAPT 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.